Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Drug Class Review: Thiazolidinediones: Final Report Update 1 [Internet].

Norris SL, Carson S, Thakurta S, Chan BKS.

Portland (OR): Oregon Health & Science University; 2008 Aug.

2.
3.

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.

PMID:
16882108
5.

A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus.

Chilcott J, Tappenden P, Jones ML, Wight JP.

Clin Ther. 2001 Nov;23(11):1792-823; discussion 1791. Review.

PMID:
11768834
6.

Rosiglitazone maleate/metformin hydrochloride: a new formulation therapy for type 2 diabetes.

Cox SL.

Drugs Today (Barc). 2004 Jul;40(7):633-43. Review.

PMID:
15510236
7.

Pioglitazone and rosiglitazone for diabetes.

[No authors listed]

Drug Ther Bull. 2001 Sep;39(9):65-8. Review.

PMID:
11586802
8.

Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.

Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R.

Clin Ther. 2005 Sep;27(9):1383-91.

PMID:
16291411
9.

Thiazolidinediones: a comparative review of approved uses.

Sood V, Colleran K, Burge MR.

Diabetes Technol Ther. 2000 Autumn;2(3):429-40. Review.

PMID:
11467345
10.
11.

Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US.

Tunis SL, Minshall ME, St Charles M, Pandya BJ, Baran RW.

Curr Med Res Opin. 2008 Nov;24(11):3085-96. doi: 10.1185/03007990802434874 . Epub 2008 Oct 2.

PMID:
18826750
12.

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483.

PMID:
16861090
13.

Spotlight on pioglitazone in type 2 diabetes mellitus.

Waugh J, Keating GM, Plosker GL, Easthope S, Robinson DM.

Treat Endocrinol. 2006;5(3):189-91.

PMID:
16677060
14.
15.
16.

Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

Intern Med J. 2007 Feb;37(2):79-86.

PMID:
17229249
17.

Drug utilization, safety and clinical use of Actos and Avandia.

Marks DH.

Int J Risk Saf Med. 2013 Jan 1;25(1):39-51. doi: 10.3233/JRS-120581. Review.

PMID:
23442297
19.
20.

Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.

Derosa G, Gaddi AV, Piccinni MN, Ciccarelli L, Salvadeo S, Peros E, Ghelfi M, Ferrari I, Cicero AF.

Pharmacotherapy. 2005 May;25(5):637-45.

PMID:
15899724

Supplemental Content

Support Center